Penumbra INC 8-K filings

Penumbra, Inc. announced its second quarter 2026 financial results, showing a 14.9% increase in total revenue to $390.0 million, driven by strong performance in both thrombectomy and embolization/access product lines.

Penumbra, Inc. announced that its stockholders have approved the merger agreement with Boston Scientific Corporation at a special meeting held on May 6, 2026.

Penumbra, Inc. announced first quarter 2026 financial results, showing a 15.6% increase in revenue to $374.8 million, with global thrombectomy revenue up 12.1% and embolization and access revenue up 23.8%.

Penumbra, Inc. announced robust financial results for the fourth quarter and full year 2025, alongside the disclosure of its proposed acquisition by Boston Scientific Corporation.

Boston Scientific Corporation will acquire Penumbra, Inc. in a cash and stock transaction valued at $374 per share, expanding its cardiovascular and neurovascular portfolios.

Penumbra, Inc. announced robust third-quarter 2025 financial results, with revenue up 17.8% to $354.7 million, and increased its full-year 2025 revenue guidance.

Penumbra, Inc. announced the promotion of Shruthi Narayan to President, effective September 1, 2025, signaling a strategic leadership transition.

Penumbra, Inc. announced robust second quarter 2025 financial results, achieving significant revenue growth and a return to net income, prompting an increase in its full-year 2025 revenue outlook.

Penumbra, Inc. announced the adoption of an Amended and Restated Certificate of Incorporation and Third Amended and Restated Bylaws, phasing in board declassification and eliminating supermajority voting requirements, following overwhelming stockholder approval.

Penumbra, Inc. announced a 16.3% increase in revenue for the first quarter of 2025, driven by strong growth in its U.S. thrombectomy business.

Don Kassing will retire from Penumbra's Board of Directors effective April 1, 2025, after 17 years of service.

Penumbra, Inc. announces positive financial results for Q4 and full year 2024, driven by U.S. thrombectomy product sales, and forecasts continued growth in 2025.

Penumbra, Inc. announced an 11.1% increase in revenue for the third quarter of 2024, driven by strong growth in its U.S. thrombectomy business.

Penumbra, Inc. has authorized a $200 million share repurchase program, including a $100 million accelerated share repurchase agreement with JPMorgan Chase Bank.

Penumbra, Inc. announced a 14.5% increase in revenue for the second quarter of 2024, alongside a revised full-year revenue guidance.

Penumbra, Inc. held its annual meeting on June 5, 2024, where stockholders voted on the election of directors, ratification of the accounting firm, and executive compensation.

Penumbra, Inc. announced a 15.4% increase in revenue for the first quarter of 2024, driven by a significant 35.2% growth in U.S. thrombectomy sales.

Penumbra Inc. has changed its independent registered public accounting firm from Deloitte & Touche LLP to PricewaterhouseCoopers LLP, effective March 17, 2024.

Penumbra, Inc. announced a robust 28.7% revenue increase for the fourth quarter of 2023 and a 25.0% increase for the full year, driven by strong thrombectomy product sales.